NCT02393417 - Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris) | Biotech Hunter

Enrollment

243

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

January 31, 2018

Study Completion Date

March 31, 2018

Conditions

Warts

Interventions

BIOLOGICAL

CANDIN

Candida albicans Skin Test Antigen for Cellular Hypersensitivity

OTHER

Placebo

0.9% Sodium Chloride Injection USP (non-preserved)

Trial Locations (15)

24501

The Education and Research Foundation, Inc., Lynchburg

27262

Dermatology Consulting Services, High Point

48059

Hamzavi Dermatology Clinical Trials, Fort Gratiot

55432

Minnesota Clinical Study Center, Fridley

72758

Northwest Arkansas Clinical Trials Center PLLC, Rogers

72916

Johnson Dermatology, Fort Smith

78218

Texas Dermatology and Laser Specialists, San Antonio

78660

Austin Institute for Clinical Research Inc., Austin

78759

DermResearch Inc., Austin

84117

Dermatology Research Center, Inc., Salt Lake City

92024

California Dermatology and Clinical Research Institute, Encinitas

92660

Silverberg MD Inc., Newport Beach

97223

Oregon Medical Research Center, Portland

02492

Metro Boston Clinical Partners, LLC, Needham

02472

BayState Clinical Trials, Watertown